Quantum Immunologics Inc.
Technology: Autologous dendritic cell immunotherapy containing oncofetal antigen/immature laminin receptor protein (OFA/iLRP)
Disease focus: Cancer
Clinical status: Phase I/II
Founded: 2008 by Charles Broes
University collaborators: University of South Alabama
Corporate partners: None
Number of employees: 18
Quantum Immunologics Inc. is developing an autologous dendritic cell therapy that it says applies lessons learned from Dendreon Corp.'s path through the clinic with Provenge sipuleucel-T.
Where Quantum says it is differentiated from other cancer immunotherapy...